OTC/Nutritional Sales & Earnings Season In Full Swing

We've been working hard at "The Tan Sheet" lately to make "cents" of all the quarterly earnings reports emerging from the OTC and nutritional industries.

In recent weeks, we've looked at firms announcing line extensions along with their financials. As we reported Aug. 2, Reckitt Benckiser plans to launch Children's Mucinex Multi-Symptom Cold Liquid in hopes of fending off generic competitors for the decongestant that loom on the horizon.   

We also broke the news that Presitge Brands introduced Little Fevers, a liquid acetaminophen extension of its Little Remedies line, to fill part of the branded product void left by Johnson & Johnson's recalled Children's Tylenol liquids.

In our Aug. 9 issue, we delve into the financial and legal prospects for Matrixx Initiatives, which continues to struggle with lawsuits and the loss of its Zicam nasal swabs, recalled last year after allegations surfaced the products caused anosmia in some users.  

Additionally, "The Tan Sheet" explores why Procter & Gamble expects new product technologies to drive top-line growth in 2011, how Herbalife's daily consumption model "is changing the face of the company," according to one analyst, and what Church & Dwight has planned for its personal care business.

And as always, "The Tan Sheet" features sales & earnings in brief -- a snapshot of companies making their own waves in the OTC and nutritional arena.

(For the latest news on financial, regulatory, legal and business developments affecting OTCs, dietary supplements and functional foods, invest in a subscription to "The Tan Sheet." To get your first issue on the house, click here.)
 

- Dan Schiff (d.schiff@elsevier.com)